Ormeloxifene in the management of dysfunctional uterine bleeding

Devi, L. Thulasi; Nimonkar, Ravi

doi:10.18203/2320-1770.ijrcog20181923

Cited by 2 publications

(2 citation statements)

References 9 publications

(9 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This leads to distortion of junctional zone, there is no evidence of proliferative endometrial tissue and hence no role of centchroman. 10 In patients of endometrial hyperplasia which was nearly 12% of the AUB patients, this drug showed poor response. The endometrial thickness in these 2 patients were 18mm and 20 mm respectively as per ultrasonography finding.…”

Section: Discussionmentioning

confidence: 99%

Centchroman use in dysfunctional and abnormal uterine bleeding after D and C

Chandrayan¹,

Naik²,

Desai³

2018

Int J Reprod Contracept Obstet Gynecol

View full text Add to dashboard Cite

Background: Incidence of DUB is more in the age group of 30-35yr and is about 35%-40%. Medical management (Centchroman) can be the treatment of preference, after excluding any organic pathology in uterus. To evaluate efficacy and side effects of Saheli (Centchroman) in case of dysfunctional uterine bleeding will depend upon the type of endometrium as determined histologically after minor procedure, D&C (Dilatation and Curettage). This drug will be used only in the presence of Proliferative Endometrium on Histopathological Examination.Methods: The study was carried out at Dhiraj Hospital, Piparia. It was an Interventional Study. 50 patients were studied in 6 months of period, 25 each of DUB and AUB. A total of 50 patients were enrolled in this study, who were attending or were admitted in the hospital. Patients who meet the inclusion criteria were included in this study, after taking prior written and informed consent.Results: Most of the patient were in the age group 39-45 years. The common complaint was excessive uterine bleeding, for which they were prescribed Centchroman. Most of the DUB patients were relieved on medication. However, few of them who had poor response to drug went for hysterectomy. It was observed that patients with early proliferative phase on HPE had better response to this drug as compared with late proliferative phase. All the patients with late proliferative phase underwent hysterectomy. Most patient with AUB including Fibroid, Adenomyosis, Endometrial hyperplasia had little or no response went for hysterectomy sooner or later on after therapy in 50% cases. Centchroman is relatively a safe drug. The most common side effect encountered was breakthrough spotting in 15 patients. 4 patients complained of amenorrhoea after 3 months of taking this drug and 1 patient complained of itching and rash over the body. No major complications were noted.Conclusions: Centchroman can be an effective non hormonal drug used for menorrhagia with proliferative endometrium with early changes in patients of DUB. This drug can also be used to control menorrhagia in patients with fibroid. This is also beneficial in patients with menorrhagia with medical illness to avert hysterectomy.

show abstract

Section: Discussionmentioning

confidence: 99%

Centchroman use in dysfunctional and abnormal uterine bleeding after D and C

Chandrayan¹,

Naik²,

Desai³

2018

Int J Reprod Contracept Obstet Gynecol

View full text Add to dashboard Cite

show abstract

“…Furthermore, a 2018 study by Devi and Nimonkar [7] showed that there was a statistically significant increase in Hb and statistically significant decrease in ET with ORM. They, therefore, concluded that ORM is safe, cost-effective, non-steroidal, and non-hormonal drug with convenient doses and better compliance, which is similar to our study.…”

Section: Vardaini Et Almentioning

confidence: 96%

Comparison of Efficacy and Safety of Ormeloxifene and Cyclical Progesterone (Norethisterone) in Ovulatory Abnormal Uterine Bleeding

Vardaini¹,

Mishra

Ranjan

et al. 2020

Asian J Pharm Clin Res

View full text Add to dashboard Cite

Objective-To determine the efficacy and safety of ormeloxifene versus progesterone in controlling Ovulatory Abnormal Uterine Bleeding(AUB-O) Methods-A Prospective Randomized comparative study of total 100 females of reproductive age group 25 to 45 years with AUB-O.Patients were randomly divided in two groups of 50 each. Results-The study showed ormeloxifene was found to be more effective and safe than Norethisterone in AUB-O. Ormeloxifine as compared to norethisterone is more effective in improving Hb and reducing endometrial thickness. Hence, ORM is more superior than Norethisterone Conclusion-In this study ormeloxifene was found to be more effective in reducing blood loss,that leads to improvement in mean haemoglobin and also it had more ability to reduce endometrial thickness.As both ormeloxifene and norethisterone are very effectivebut ormeloxifene is safe , cost effective ,nonsteroidal, non hormonal drug with convenient dosage and better compliance for medical management of AUB-O.Hence, ormeloxifene canbe considered as first drugs in the management of AUB-O.

show abstract

Ormeloxifene in the management of dysfunctional uterine bleeding

Cited by 2 publications

References 9 publications

Centchroman use in dysfunctional and abnormal uterine bleeding after D and C

Centchroman use in dysfunctional and abnormal uterine bleeding after D and C

Comparison of Efficacy and Safety of Ormeloxifene and Cyclical Progesterone (Norethisterone) in Ovulatory Abnormal Uterine Bleeding

Contact Info

Product

Resources

About